Introduction {#s1}
============

*Polygonum multiflorum* (PM), the root of *Polygonum multiflorum* Thunb., has been applied in clinic for more than a thousand years with remarkable efficacy as nourishing Chinese medicine (Lin L. et al., [@B25]; Zhang et al., [@B49]). The long application history in China rarely reported PM toxicity in ancient herbal works. But in recent years, Medicines and Healthcare Products Regulatory Agency in British and Adverse Drug Reactions Advisory Committee in Australia have released the warning message in liver injury of PM since 2006 (Cárdenas et al., [@B2]; Cho et al., [@B4]; Wu et al., [@B45]; Dong et al., [@B6]). China Drug and Food Administration issued a warning message of liver injury with PM preparations in 2013 (Lian et al., [@B23]; Miao and Yun, [@B31]). Since then, more than 100 cases of liver damage were reported which has attracted worldwide attention to PM safety as a commonly used traditional Chinese medicine (Teschke et al., [@B43]; Lei et al., [@B19]). Therefore, it is necessary to clarify the related mechanism of liver injury caused by PM and provide scientific basis for clinical rational drug use.

Metabolomics study the species, quantity and changes of organism endogenous metabolites. Through a comprehensive and systematic investigation of the metabolic profiles change, metabolomics analyze the difference of metabolic fingerprints and obtain the corresponding biomarkers combined with pattern recognition and other chemical information technology (Bose et al., [@B1]; Li et al., [@B21]; Su et al., [@B41]). Then qualitative analysis and quantitative determination of biomarkers are carried out to reveal the relationship and dynamic laws between physiological and pathological changes (Ma et al., [@B28]; Zhang et al., [@B48]).

Some metabolomics studies have been carried out to investigate the HSW toxicity. A targeting quantitative metabolomics reported the effect of PM on liver damage concentrating on nine kinds of bile acid changes (Dong et al., [@B7]). A study investigated the effect of different extract of PM on idiosyncratic drug-induced liver injury (Li et al., [@B20]), and another urine metabolomics study evaluated the liver toxicity of PM extract by 75% ethanol--water (Zhang et al., [@B47]). As we know, traditional Chinese medicine is always decocted with water in clinical application and the dosage is also a key factor influencing the herb toxicity. However, no related report can be found in investigating the impairment level of different PM dosage on liver damage. And most reported study used the HSW extract by organic solvent which was not in accordance with the actual clinical application.

Therefore, serum samples from rats with liver injury were systematically investigated using traditional biochemical analysis, pathological observation and non-targeted metabolomics method to evaluate the relationship between the dosage of PM and liver damage. The metabolic profiles of serum of rats with liver injury and normal rats were analyzed to screen serum biomarkers of metabolic disorders caused by liver damage. The metabolic pathways were explored by combining the biochemical indexes and metabolic markers to clarify liver injury mechanism of PM.

Experimental contents {#s2}
=====================

Chemicals and reagents
----------------------

Methanol, acetonitrile and formic acid were HPLC grade and purchased from Fisher Co. (Pittsburg, PA, USA). Purified water was prepared by a Milli-Q ultrapure water system (Millipore, Bedford, MA, USA). Other chemicals were analytical grade. The dry roots of Raw PM (*Polygonum multiflorum* Thunb.) were purchased from Sichuan Qinbashan Chinese Herbal Medicines Pieces Ltd. (Bazhong City, Sichuan province, China) and authenticated by Prof. Jin Pei (The section of pharmacognosy, Chengdu University of traditional Chinese medicine, China).

Animals
-------

48 SPF Sprague-Dawley rats (200 ± 20 g) were obtained from the Laboratory Animal Center of Sichuan Academy of Traditional Chinese Medicine (Certification number SCXK 2013-19). All animals were acclimated for 7 days before the experiment. They were housed in an environmentally controlled room at a constant temperature (22 ± 2°C) and humidity (50 ± 2%) on a 12 h light/dark cycle and provided with standard diet and water. This study was carried out in accordance with the recommendations of "the Guide for the Care and Use of Laboratory Animals (NIH publication \#85-23, revised in 1985) and the Guiding Principles for the Care and Use of Laboratory Animals of China." And the experiment involving biohazards, biological agents and reagents was carried out under "the guidance of safety procedure of Chengdu University of Traditional Chinese Medicine." The protocol was approved by "the ethical committee of Chengdu University of Traditional Chinese Medicine (No. 20160705)."

Preparation of drugs
--------------------

The plant quality was important in the toxicity evaluation. In previous experiment, fingerprint analysis of PM has been carried out in 25 batches of raw PM samples purchased from different provinces of China to compared the herb quality of different sources. Raw PM from Dabashan, Sichuan Province was chosen for toxicity evaluation (Li et al., [@B22]). The contents of 16 chemical compounds including gallic acid, procyanidinsB1, catechin, gallate, aloe emodin-8-β-o-glucoside, polydatin, stilbene glycosides, rhaponticin, resveratrol, emodin-8-β-o-glucoside, physcion-8-β-o-glucoside, aloe emodin, rhein, emodin, chrysophanol, and physcion were 107.43, 106.45, 851.87, 287.30, 108.62, 277.66, 43,982.58, 1,180.41, 311.32, 3,234.45, 463.20, 59.93, 35.86, 1,287.06, 4.58, 656.47 μg/g, respectively.

Raw PM was soaked for 2 h with 10 times of water, and then boiled for two times (2, 1.5 h respectively). The filtrate was collected after extraction and concentrated by rotary evaporators at 60°C. The final 2 g crude PM/mL was stored at 4°C for experiment.

Drug administration
-------------------

According to Chinese Pharmacopoeia, 3\~6 g raw PM was suggested for human clinical application. After transformation from human to rat, the clinical dosage for rat was 0.3125\~0.625 g/kg. In the long term toxicity experiment, it was usually recommended that 10--30 times of the clinical dosage was used as the low dose, 30--50 times as the middle dose, 50 and 100 times as the high dose. Considering the requirement and the actual administration volume, 10, 20, 40 g/kg were chosen as the low, middle and high dosage in this experiment, respectively.

The animals were randomly divided into four groups, including control group, raw PM high dose group (PMR-H), raw PM middle dose group (PMR-M) and raw PM low dose group (PMR-L). PMR-H, PMR-M and PMR-L was orally administered of 40.0, 20.0, 10.0 g/kg raw PM once per day for 28 days, respectively. Control group was orally given an equivalent volume of distilled water. The sign, behavior, urine, defecation and secretions were observed every day. The body weight was recorded on the 1st, 4th, 7th, 10th, 13th, 16th, 19th, 22nd, 25th, and 28th day, and the body weight growth rate was calculated.

Samples collection
------------------

Twelve hour after last administration, the blood samples were collected from the rat abdominal aorta and incubated at 37°C for 30 min. Then the blood samples were centrifuged at 3,500 g for 10 min and the supernatant serum was transferred into clean plastic tube for blood biochemical analysis and metabolomics analysis. The livers were removed from the rats immediately after sacrifice.

Sample analysis
---------------

### Serum biochemistry and histopathological analysis

According to the kit instruction, the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total protein (TP), total bilirubin (T-BIL), direct bilirubin (D-BIL), total cholesterol (TC), triglycerides (TG) and total bile acid (TBA) were measured by Mindray BS-300 automatic biochemistry Analyzer (Shanghai Fuzhong Biosciences Corporation, China). For histopathological examination, liver tissues were fixed and preserved in 10% neutral formalin, and embedded in paraffin after dehydration. The slices (5 mm) were observed after being stained with hematoxylin and eosin (HE).

### Metabolomics study of serum samples

Three hundred microliter serum samples were mixed with 600 μL methanol for 1 min. The samples were collected after being centrifuged at 12,000 rpm at 4°C for 10 min and the supernatant was transferred to centrifuge tube and filtered through microporous membrane (0.22 μm). The quality control (QC) sample was prepared in an equal volume of all samples, and QC sample was detected every 10 samples throughout the injection.

Metabolomics analysis was performed on Agilent 1290 UPLC-6540 Q-TOF MS/MS (Agilent Technologies, Palo Alto, USA) system which was equipped with a binary solvent delivery and an auto sampler. Analysis was carried out on an UPLC BEH C~18~ column (1.7 μm, 2.1 × 100 mm) at 40°C. The mobile phase was a mixture of solvent A (Water with 0.1% formic acid) and solvent B (Acetonitrile with 0.1% formic acid). The gradient elution was optimized as following: 0\~0.5 min, B (2%); 0.5\~9 min, B (2% \~50%); 9.0\~12.0 min, B (50%\~98%); 12.0\~13.0 min, B (98%), 13.0\~14.0 min, B (98%\~2%), 14.0\~15.0 min, B (2%). The flow rate was set at 0.30 mL/min. 8 μL supernatant were injected for UPLC-Q-TOF-MS analysis.

MS condition: Electrospray voltage was 5.5 kV in positive ionization mode and 4 kV in negative ionization mode. Declustering potential was 80 V and the source temperature was 600°C. The curtain gas was 35 psi and the nebulizer was 45 pisg for positive and 35 pisg for negative. The sheath gas flow was 12 L/min at 350°C. Calibrations were automatically conducted from m/z 50--1,000 with sodium formate solution.

Data processing and pattern recognition analysis
------------------------------------------------

### Data pre-processing

UPLC-MS data was converted into cdf format by Protein Wizard software and XCMS ([www.bioconductor.org/](http://www.bioconductor.org/)) was used to extract the peak data, peak denoise, peak matching, peak alignment, export and save the results for non-target metabolomics. In each sample, peak areas of metabolites were normalized by sum method applied in metaboanalyst ([www.metaboanalyst.ca](http://www.metaboanalyst.ca)). A data set of all samples, consisting of retention time and normalized peak area of metabolites, was imported into Simca-P software (version 13.0, Umetrics AB, Umea, Sweden) for data pre-processing. The data were processed by unit variance scaling and mean-centered method, followed by multivariate analysis, including principal component analysis (PCA) and partial least squares-discriminant analysis (PLS-DA). Permutation test was used to prevent overfitting of the OPLS-DA model. Variables with importance parameters value higher than 1 (VIP \> 1.0) in OPLS-DA model were selected as potential variables. SPSS 21.0 (Chicago, IL, USA) software was used to perform Student\'s *t*-test and One-way analysis of variance (ANOVA) for these variables. Metabolites with *p* \< 0.05 (ANOVA and *t*-test) and fold change value \>1.5 were considered to be statistically significant.

### Biomarker identification and metabolic pathway analysis

The significant metabolic biomarkers were screened using the exact molecular ion measured by MS/MS. The potential biomarkers were tentatively identified by matching the accurate mass charge ratio and MS/MS fragmentation patterns to the online database (20 ppm as the accepted mass error) such as METLIN database (<http://www.metlin.scipps.edu/>) and HMDB database (<http://www.hmdb.ca/>). The pathways of potential biomarkers was analyzed using MetaboAnalyst 3.0 (<http://www.metaboanalyst.ca/>). Rattus norvegicus (rat) (81) for pathway path library was selected for pathway enrichment and topological analysis, and other parameters were set at default.

Results {#s3}
=======

Behavioral observations
-----------------------

The rats in control and PWR-L groups had normal mental activity, smooth body hair, normal urine and defecation. However, the behavioral activity of rats decreased with yellow hair and filthy crissum in PWR-M and PWR-H groups. The body weight of each group increased with time, and no significant difference was observed among groups during study period (Figure [1](#F1){ref-type="fig"}). Table [1](#T1){ref-type="table"} showed that the liver of rats in PWR-M and PWR-H groups had a certain degree of swelling and the organ coefficients (calculated as Equation 1) were significantly higher than that of the control group. As a commonly used toxicology indicator, organ coefficient reflected the liver toxicity of middle and high doses of Raw PM.
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![Body weight of rats in each groups in 28 days.](fphar-08-00791-g0001){#F1}

###### 

The organ weight and organ coefficient of liver in each group ($\overline{x} \pm s$, *n* = 12).

  **Group**   **W/g**          **Liver**      
  ----------- ---------------- -------------- ------------------------------------------------
  BC          258.68 ± 30.04   8.18 ± 1.20    3.16 ± 0.48
  PMR-L       248.65 ± 24.75   8.04 ± 1.00    3.23 ± 0.40
  PMR-M       248.75 ± 50.15   9.89 ± 1.51    3.98 ± 0.57[^\*^](#TN1){ref-type="table-fn"}
  PMR-H       244.64 ± 33.53   10.41 ± 1.57   4.25 ± 0.65[^\*\*^](#TN2){ref-type="table-fn"}

*Compared with the control group*,

*p \< 0.05*,

*p \< 0.01. W, weight; Coe, organ coefficient*.

Biochemical analysis and histopathological observations
-------------------------------------------------------

The results of biochemical analysis were shown in Table [2](#T2){ref-type="table"} and Figures [2A--I](#F2){ref-type="fig"}. Compared with the control group, the contents of ALT, AST, ALP, TG and TBA in PMR-M and PMR-H group were significantly increased (*P* \< 0.05 or *P* \< 0.01). Meanwhile, the contents of T-Bil, D-Bil, TC, and TP in serum were significantly decreased (*P* \< 0.05 or *P* \< 0.01). However, except serum AST, TG, T-Bil and D-Bil, no significant differences were observed between PMR-L group and the control group.

###### 

The results of biochemical analysis in rats of liver injury ($\overline{x} \pm s$, *n* = 12).

  **Index**         **BC**           **PMR-H**                                           **PMR-M**                                           **PMR-L**
  ----------------- ---------------- --------------------------------------------------- --------------------------------------------------- ---------------------------------------------------
  ALP (U/L)         195.73 ± 46.23   264.48 ± 80.97[^\*\*^](#TN4){ref-type="table-fn"}   229.05 ± 66.04[^\*^](#TN3){ref-type="table-fn"}     213.87 ± 82.42
  AST (U/L)         75.95 ± 22.98    131.80 ± 21.84[^\*\*^](#TN4){ref-type="table-fn"}   119.20 ± 18.48[^\*\*^](#TN4){ref-type="table-fn"}   114.36 ± 21.11[^\*\*^](#TN4){ref-type="table-fn"}
  ALT (U/L)         39.24 ± 7.58     57.23 ± 48.70[^\*\*^](#TN4){ref-type="table-fn"}    48.48 ± 8.32[^\*^](#TN3){ref-type="table-fn"}       36.90 ± 5.44
  TG (mmol/L)       0.36 ± 0.39      0.70 ± 0.54[^\*\*^](#TN4){ref-type="table-fn"}      0.59 ± 0.25[^\*\*^](#TN4){ref-type="table-fn"}      0.57 ± 0.25[^\*\*^](#TN4){ref-type="table-fn"}
  TBA (μmol/L)      26.74 ± 6.67     40.13 ± 4.99[^\*^](#TN3){ref-type="table-fn"}       37.98 ± 7.08[^\*^](#TN3){ref-type="table-fn"}       34.44 ± 5.46
  TC (mmol/L)       1.91 ± 0.22      1.08 ± 0.30[^\*\*^](#TN4){ref-type="table-fn"}      1.37 ± 0.27[^\*^](#TN3){ref-type="table-fn"}        1.56 ± 0.25
  T-Bill (μmol/L)   2.01 ± 0.30      0.94 ± 0.53[^\*\*^](#TN4){ref-type="table-fn"}      1.31 ± 0.40[^\*^](#TN3){ref-type="table-fn"}        1.41 ± 0.44[^\*^](#TN3){ref-type="table-fn"}
  D-Bill (μmol/L)   1.81 ± 0.26      0.55 ± 0.30[^\*\*^](#TN4){ref-type="table-fn"}      0.88 ± 0.29[^\*\*^](#TN4){ref-type="table-fn"}      1.09 ± 0.43[^\*\*^](#TN4){ref-type="table-fn"}
  TP (g/L)          62.36 ± 2.98     52.88 ± 3.98                                        59.33 ± 2.66                                        62.75 ± 3.58

*Compared with the control group*,

*p \< 0.05*,

*p \< 0.01*.

![**(A--I)** The serum levels of ALP, AST, ALT, TG, TBA, TC, T-BIL, D-BIL, and TP. Compared to the control group, ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01. One-way analysis of variance (ANOVA) was used to calculate significant difference.](fphar-08-00791-g0002){#F2}

After hematoxylin-eosin (HE) staining, the structure of normal liver cells observed under microscopy (Figure [3](#F3){ref-type="fig"}) showed that the uniform liver cells were cord-like arranged with the clearly visible nucleus and nuclear membrane. After administration of Raw PM, cell shrinking appeared with disordered cord arrangement. Karyopyknosis was detected with blurred structure, and the edge was unclear. Combined the results of biochemical analysis and pathology analysis, the liver function lesion was found in rats after Raw PM administration. Severer hepatocellular cytopathic effect was found with the increased dose.

![Representative light photomicrographs of rat liver specimens for HE analysis (400^\*^ magnification).](fphar-08-00791-g0003){#F3}

Multivariate statistical analysis and potential biomarkers
----------------------------------------------------------

Serum chromatography was obtained by UPLC-Q-TOF-MS in both positive ion and negative ion mode. To obtain the difference of metabolic components among the four group samples, the multivariate statistical analysis method was used to investigate the serum metabolites of each sample.

After the peak matching, all the variables of the control group and PMR groups were analyzed by PCA. An anomaly sample was removed in the clustering of the data and the result score plots of positive and negative modes were shown in Figures [4A,B](#F4){ref-type="fig"}. As the picture showed, an obvious separation trend can be observed among the control and three PMR groups in both positive and negative models. Although a part coincide can be observed between the PMR-M and PMR-H group or PMR-M and PMR-L groups. The separation between PMR-H and PMR-L was achieved completely. The results suggested that there were a considerable metabolite difference between the control group and drug administration groups. Significant metabolic differences between the PMR-H and PMR-L group indicated that further multivariate statistical analysis was necessary to discern the relationship among these three administration dosage.

![PCA score plots and OPLS-DA score plots of different groups of PM in ESI^+^ and ESI^−^ mode respectively. The score plots of PCA of BC, RPM-L, PMR-M, and PMR-H groups from PCA in ESI^+^ **(A)** and ESI^−^ **(B)** for BC group vs. PMR-L, PMR-M, PMR-H groups. The score plots of OPLS-DA of BC, PMR-L, PMR-M, and PMR-H groups from PCA in ESI^+^ **(C)** and ESI^−^ **(D)** for BC group vs. PMR-L, PMR-M, PMR-H groups. Metabolites with VIP \> 1 were marked with a red triangle in ESI^+^ **(E)** and ESI^−^ **(F)**. 200-permutation test of PLS-DA model in ESI^+^ **(G)** and ESI^−^ **(H)**.](fphar-08-00791-g0004){#F4}

As a supervised method, OPLS-DA was applied to further confirm the potential biomarkers of liver damage caused by PM. The results of OPLS-DA model derived from data of ESI^+^ and ESI^−^ analysis was displayed in Figures [4C--H](#F4){ref-type="fig"}. Figures [4C,D](#F4){ref-type="fig"} showed obvious separation among four groups. The samples of control group clustered together and remained relatively far from other three PMR groups. Among the three PMR groups, PMR-L and PMR-M groups separated with relatively closer distance. While the samples of PMR-H group fell far apart and aggregated in another region. The parameter R^2^Y and Q^2^ obtained by cross-validation were 0.912 and 0.625 in positive mode, 0.888 and 0.647 in negative mode (Figures [4G,H](#F4){ref-type="fig"}), which indicated the good predictive ability of how well the model fit the data. Loading plot with Figures [4E,F](#F4){ref-type="fig"} suggested the potential metabolites with variable influence on the projection (VIP \> 1) which were flagged with a red triangle. Permutation test in Figures [4G,H](#F4){ref-type="fig"} was performed using 200 iterations in order to prevent over-fitting of the OPLS-DA model, and the results showed that the model was not over-fitted.

The selection, identification, and analysis of potential biomarkers
-------------------------------------------------------------------

According to variable importance of the project (VIP), the differentiated metabolites with VIP value \> 1 from the OPLS-DA score plots was selected for further *T*-test and ANOVA analysis using SPSS 21.0 software. Non-parametric tests were performed to statistically identify significant differences in metabolites with *P* \< 0.05 and 1.5-fold-change \> 1.5 between the control group and three PMR groups. Through the above two steps, differentiated metabolites related to liver injury of Raw PM were screened out. Based on the accurate mass number, retention time, MS/MS information of the metabolites, the metabolite ions were identified by the combination of online database information and standard sample spectra. Combined with the accurate mass-to-charge ratio in METLIN database and HMDB database, a total of 9 metabolites in positive and negative ion mode had been differentially expressed between in control and PMR groups. The results were summarized in Table [3](#T3){ref-type="table"} and the relative concentrations of 9 metabolites were shown in Figure [5](#F5){ref-type="fig"}. The important plasma biomarkers related to liver injury were further analyzed and the possible metabolic pathway of PM-induced toxicity was displayed in Figure [6](#F6){ref-type="fig"}.

###### 

List of the identification of potential biomarkers among groups.

  **No**.   **rt/min**   **Mass**   **Type**     **ppm**   **Identified compound**        **Formula**
  --------- ------------ ---------- ------------ --------- ------------------------------ ---------------------
  1         2.03         104.0473   \[M-H\]^−^   5         D(--)-β-hydroxy butyric acid   C~4~H~8~O~3~
  2         3.91         297.0849   \[M+H\]^+^   1         5-Methylthio adenosine         C~11~H~15~N~5~O~3~S
  3         4.57         213.0096   \[M-H\]^−^   0         Indoxyl sulfate                C~8~H~7~NO~4~S
  4         4.65         133.0528   \[M+H\]^+^   3         Oxindole                       C~8~H~7~NO
  5         5.98         188.0143   \[M-H\]^−^   0         p-Cresyl sulfate               C~7~H~8~O~4~S
  6         10.02        390.277    \[M+H\]^+^   7         Bis(2-ethylhexyl) phthalate    C~24~H~38~O~4~
  7         10.44        343.2722   \[M+H\]^+^   1         Dodecanoyl carnitine           C~19~H~37~NO~4~
  8         11.5         286.2144   \[M-H\]^−^   0         Hexadecanedioic acid           C~16~H~30~O~4~
  9         11.55        399.3349   \[M+H\]^+^   1         Palmitoyl carnitine            C~23~H~45~NO~4~

![Schematic diagram of the metabolic pathway related to PM induced rat liver injury. The boxes bordered in red and purple represent metabolites that are significantly higher and lower in the PM groups than in BC group, respectively. The light green and light blue boxes indicate metabolites significantly higher and lower in the model group than in the control group, respectively. The related metabolic pathways are cycled in a black box; ALT, glutamate pyruvate transaminase; AST, aspartate aminotransferase.](fphar-08-00791-g0005){#F5}

![Variations in the trends of the metabolites that are biomarkers. **(A--I)** shown are the variations in the trends of D(--)-β-hydroxy butyric acid, 5-methylthio adenosine, indoxyl sulfate, oxindole, *p*-Tolyl sulfate,bis(2-ethylhexyl) phthalate, dodecanoyl carnitine, hexadecanedioic acid, palmitoyl carnitine, respectively. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01 compared with the control group, respectively.](fphar-08-00791-g0006){#F6}

Discussion {#s4}
==========

Biochemical analysis and histopathological change
-------------------------------------------------

The changes of serum ALT, AST, and ALP reflected the damage degree of liver cells (Franson, [@B10]; Penndorf et al., [@B35]; Kunutsor et al., [@B18]). The levels of rat serum ALT, AST, and ALP exposed to middle and high dose of Raw PW were significantly increased, which indicated that the liver cell membrane was impaired and the release of them into blood was increased after PMR administration. Indirect bilirubin was taken and metabolized to D-Bil by liver cells. The function impairment of metabolic synthesis and bile secretion caused by liver damage resulted in the decreased D-Bill content. The content of T-Bill, the combination of indirect bilirubin and D-Bill, may be corresponding reduced with the decrease D-Bill content. The level of TBA reflected the function of liver synthesis and reabsorption (Henkel et al., [@B15]; Ferslew et al., [@B8]). When the liver was damaged, it cannot effectively re-intake TBA for enterohepatic circulation, which caused the increased TBA level in blood. TP directly reflected the anabolic function of liver cells (Tanaka et al., [@B42]; Gao et al., [@B12]). The decreased blood TP had a positive correlation to the degree of liver synthesis capacity dysfunction. Serum TG and TC levels also responded to the energy metabolism of the liver function (Frajacomo et al., [@B9]; Chen et al., [@B3]). The biochemical results showed that PMR could damage the liver by affecting the synthesis, transformation, secretion and energy metabolism of the liver.

Lipid metabolism, amino acid metabolism, and bile acid metabolism involved in PMR liver toxicity
------------------------------------------------------------------------------------------------

In previous report, the mechanism of hepatotoxicity induced by PM has been investigated related to the determination of biochemical markers and the analysis of metabolomics (Wang et al., [@B44]; Xia et al., [@B46]). The hepatitis biochemical results showed AST, ALT, glutamyl transpeptidase (GGT), TBA increase, and superoxide dismutase (SOD) and TBIL significant reduction. The biochemical results of our experiment were consistent with the results of these literatures. The mechanism of hepatotoxicity reported mainly includes: bile acid metabolism (Dong et al., [@B7]), sphingolipid metabolism and tricarboxylic acid cycle (Li et al., [@B20]), vitamin B6 metabolism and tryptophan metabolism (Zhang et al., [@B47]). In this study, non-targeted metabolomics was used to analyze the liver toxicity of PM decoction, and the results showed that fatty acid metabolism, amino acid metabolism and bile acid metabolism were involved in the toxicity mechanism.

### Metabolites alteration related to fatty metabolism in raw PM liver toxicity

As a necessary nutrient for the body, free carnitine played a vital role in energy production and fatty acid metabolism. Under normal circumstances, intracellular long-chain fatty acid formed and transformed into fatty acyl CoA under the action of the ester of acyl CoA synthetase which was located in the endoplasmic reticulum and mitochondrial outer membrane (Gao et al., [@B13]; Paczkowski et al., [@B33]; Meadows and Wargo, [@B30]). To complete β-oxidation, the fatty acyl CoA had to be combined with L-carnitine to form carnityl carnitine to enter mitochondria under the action of carnitine acyltransferase I (CPT-I), and then later released L-camitine by carnitine acyltransferase (CPT-II). Then fatty acyl CoA in mitochondria was β-oxidized to form acetyl-CoA (Prip-Buus et al., [@B37]; Fulgencio et al., [@B11]; Skrede et al., [@B39]). In this study, the significantly reduced long-chain acyl carnitine may be caused by the impaired activity of fatty acid esterase or CPTI which was the results of PM induced liver damage. Due to the decrease of long chain acyl carnitine, the content of fatty acids that can be oxidized and decomposed was reduced. Corresponding, the formation of the intermediate product of ketone bodies oxidative decomposition, such as acetoacetic acid, β-hydroxybutyric acid and acetone was reduced.

### Metabolites alteration related to bile acid metabolism in raw PM liver toxicity

As the intermediate product of glycometabolism, lipid metabolism and protein metabolism, acetyl CoA was involved in the synthesis of total cholesterol under the action of hydroxymethylglutarate CoA reductase (HMG-CoA). Total cholesterol was catalyzed by 7A-hydroxylase to produce bile acid (TBA) which entered the liver and gut circulation (Parker et al., [@B34]; Jiang et al., [@B16]). The liver was injured and cannot effectively retake TBA in the enterohepatic circulation, leading to increased blood TBA content, which decreased cholesterol content by inhibiting cholesterol formation through the body feedback regulation. The damaged liver resulted in the weakened capacity of hepatocytes uptake, binding and secretion (Luo et al., [@B27]; Masubuchi et al., [@B29]). Also, the reduced uptake of free bilirubin (B-Bil) by liver cell resulted in the decreased binding of B-Bill and albumin to produce direct bilirubin (D-Bil) (Liu et al., [@B26]). Therefore, the amount of D-Bill discharged into the blood through the bile acids was reduced.

### Metabolites alteration related to amino acid metabolism raw PM liver toxicity

The metabolite sulfuric acid p-cresol, produced from the amino acid phenylalanine and tyrosine by intestinal anaerobic bacteria, and the metabolite indole phenol sulfate, produced from the tryptophan decomposition products indole, were the representative substances of uremic toxins. Both sulfuric acid p-cresol and indole phenol sulfate had vascular toxicity and nephrotoxicity (Raff et al., [@B38]; Gironès et al., [@B14]). Sulfated acid p-cresol caused stress response in renal tubular cells, stromal cells, vascular smooth muscle cells through the induction of systemic oxidative stress reaction, and inhibiting endothelial proliferation and repair which led to chronic kidney disease (Poveda et al., [@B36]). Indole phenol sulfate promoted renal interstitial mononuclear/macrophage infiltration, produced a variety of fibrosis factors and induced renal interstitial fibrosis (Lin C. J. et al., [@B24]). The increased levels of the two components indicated that Raw PM not only damaged the liver, but also injured the kidneys in a certain degree.

*In vivo*, Amino acid was partly deaminized and entered blood to form blood ammonia. In the liver, arginine was hydrolyzed through the ornithine cycle to produce urea which was excreted by the kidney. Part of Amino acid was transformed into ionic ammonia by the kidney and excreted with the urine. Glutamine was produced by amino acid and glutamic acid which was originated from α-ketoglutaric acid by ALT and AST enzyme catalyzation in tricarboxylic acid cycle (Sözen et al., [@B40]; Miles et al., [@B32]). The long term administration of Raw PM resulted in liver damage with the decreased function of transforming blood ammonia to urea. And the accumulation of blood ammonia aggravated the degree of liver injury (Daijo et al., [@B5]; Kido et al., [@B17]). Then the formation of glutathione precursor adenosine methionine (SAM) was reduced, and the level of its metabolite, 5-methylthio adenosine MTA, was corresponding reduced.

Conclusion {#s5}
==========

This study systematically carried out the toxicity investigation of PMR based on biochemical analysis, histopathological observation and metabolomics study. The related biomarkers of liver injury induced by Raw PM were screened based on metabolomics study. Pathway analysis showed that the liver damage was induced through amino acid metabolism, lipid metabolism and bile acid metabolism disorder which were in accordance with results of biochemical analysis and histopathological observations. The results showed that there was a certain correlation between the liver injury and the dose of PM. In the tested dosage range, 30 times of clinical dosage (10 g/kg for rat in the experiment) caused little liver toxicity which suggested the safety of Raw PM with normal dosage. But the potential hepatic and renal toxicity occurred with 20 and 40 g/kg also warned us not to take higher dosage of PM for a long time.
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